During March 2016, 750 Class A shares were converted to Class B shares, at the request of a shareholder. The total number of votes in RaySearch thereafter amounts to 126,641,349 votes. The total number of registered shares in RaySearch amounts to 34,282,773 shares, of which 10,262,064 are Class A shares and 24,020,709 are Class B shares.
According to RaySearch Laboratories AB (publ)’s Articles of Association, owners of Class A shares have the right to have such shares converted to Class B shares. A conversion reduces the number of votes in the company. When a conversion has been carried out, RaySearch is obligated by law to disclose information on the changes occurred by the conversion.
RaySearch Laboratories AB (publ) is a medical technology company that develops advanced software solutions for improved radiation therapy of cancer. RaySearch markets the RayStation® treatment planning system to clinics all over the world. In addition, RaySearch’s products are distributed through licensing agreements with leading medical technology companies. RaySearch’s software solutions are used by over 2,600 clinics in more than 65 countries. RaySearch was founded in 2000 as a spin-off from Karolinska Institutet in Stockholm and the company is listed in the Mid Cap segment on NASDAQ OMX Stockholm.
For more information about RaySearch, visit www.raysearchlabs.com.
For further information please contact:
RaySearch Laboratories AB (publ)
Johan Löf, President and CEO, RaySearch Laboratories AB (publ)
Telephone: +46 (0)8-510 530 00
RaySearch discloses the information provided herein pursuant to the Securities Market Act and/or the Financial Instruments Trading Act.